Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration

Hung,Kuo-Chen; Hsieh,Pei-Min; Yang,Kun-Lin; Lin,Kai-Jen; Chen,Yaw-Sen; Hung,Chih-Hsin

doi:10.3892/ol.2012.1089

Effect of thalidomide on the expression of vascular endothelial growth factor in a rat model of liver regeneration

Authors:
- Kuo-Chen Hung
- Pei-Min Hsieh
- Kun-Lin Yang
- Kai-Jen Lin
- Yaw-Sen Chen
- Chih-Hsin Hung
View Affiliations

Affiliations: Institute of Biotechnology and Chemical Engineering, I-Shou University, Kaohsiung, Taiwan, R.O.C., Department of Surgery, Division of General Surgery, E-DA Hospital/I-Shou University, Kaohsiung, Taiwan, R.O.C., Institute of Basic Medical Sciences College of Medicine, National Cheng Kung University, Tainan, Taiwan, R.O.C., Department of Pathology, E-DA Hospital/I-Shou University, Kaohsiung, Taiwan, R.O.C.
Published online on: December 20, 2012 https://doi.org/10.3892/ol.2012.1089
Pages: 852-856

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Liver regeneration is an angiogenesis-associated phenomenon. The present study investigated the influence of thalidomide, an antiangiogenic agent, on vascular endothelial growth factor (VEGF) expression and liver regeneration after 70% partial hepatectomy (PH) in rats. PH was performed on 50 rats dosed with either thalidomide (100 mg/kg) or a vehicle (controls) by intragastric administration. Serial changes in hepatic microcirculation were evaluated by laser Doppler flowmetry. The VEGF expression in liver tissue was assessed by immunohistochemical study and western blot analysis. Following hepatectomy, the liver regeneration rate increased markedly and reached a peak at 96 h in the two groups. Thalidomide did not affect the overall restoration of liver mass, although a delay in cell proliferation was observed. Prior to PH, the liver microcirculation in rats treated with thalidomide for 2 days was comparatively less than that in their corresponding controls; however, no significant difference between the groups was detected at any time-point following PH. Western blotting showed that the expression of VEGF was upregulated by hepatectomy and the expression levels in the two groups were equal at all studied time-points. The immunohistochemical staining revealed a waved pattern of VEGF expression which advanced from the periportal to pericentral area in both groups, but a slower advancement was detected in thalidomide-treated rats. In conclusion, thalidomide exerted no significant effects on the expression of VEGF and did not impair the overall restoration of liver mass in a rat model of PH-induced liver regeneration, providing supportive evidence for its use as an adjunct treatment modality for liver cancers.

View Figures

View References

1	Michalopoulos GK and DeFrances MC: Liver regeneration. Science. 276:60–66. 1997. View Article : Google Scholar
2	Mohammed FF and Khokha R: Thinking outside the cell: proteases regulate hepatocyte division. Trends Cell Biol. 15:555–563. 2005. View Article : Google Scholar : PubMed/NCBI
3	Fausto N, Laird AD and Webber EM: Liver regeneration. 2 Role of growth factors and cytokines in hepatic regeneration. FASEB J. 9:1527–1536. 1995.PubMed/NCBI
4	Drixler TA, Vogten MJ, Ritchie ED, et al: Liver regeneration is an angiogenesis-associated phenomenon. Ann Surg. 236:703–712. 2002. View Article : Google Scholar : PubMed/NCBI
5	Taniguchi E, Sakisaka S, Matsuo K, Tanikawa K and Sata M: Expression and role of vascular endothelial growth factor in liver regeneration after partial hepatectomy in rats. J Histochem Cytochem. 49:121–130. 2001. View Article : Google Scholar : PubMed/NCBI
6	Leung DW, Cachianes G, Kuang WJ, Goeddel DV and Ferrara N: Vascular endothelial growth factor is a secreted angiogenic mitogen. Science. 246:1306–1309. 1989. View Article : Google Scholar : PubMed/NCBI
7	McBride WG: Thalidomide embryopathy. Teratology. 16:79–82. 1977. View Article : Google Scholar : PubMed/NCBI
8	D’Amato RJ, Loughnan MS, Flynn E and Folkman J: Thalidomide is an inhibitor of angiogenesis. Proc Natl Acad Sci USA. 91:4082–4085. 1994.
9	Kenyon BM, Browne F and D’Amato RJ: Effects of thalidomide and related metabolites in a mouse corneal model of neovascularization. Exp Eye Res. 64:971–978. 1997. View Article : Google Scholar : PubMed/NCBI
10	Kruse FE, Joussen AM, Rohrschneider K, Becker MD and Völcker HE: Thalidomide inhibits corneal angiogenesis induced by vascular endothelial growth factor. Graefes Arch Clin Exp Ophthalmol. 236:461–466. 1998. View Article : Google Scholar : PubMed/NCBI
11	Singhal S, Mehta J, Desikan R, et al: Antitumor activity of thalidomide in refractory multiple myeloma. N Engl J Med. 341:1565–1571. 1999. View Article : Google Scholar : PubMed/NCBI
12	Little RF, Wyvill KM, Pluda JM, et al: Activity of thalidomide in AIDS-related Kaposi’s sarcoma. J Clin Oncol. 18:2593–2602. 2000.
13	Hsu C, Chen CN, Chen LT, et al: Low-dose thalidomide treatment for advanced hepatocellular carcinoma. Oncology. 65:242–249. 2003. View Article : Google Scholar : PubMed/NCBI
14	Pinter M, Wichlas M, Schmid K, et al: Thalidomide in advanced hepatocellular carcinoma as antiangiogenic treatment approach: a phase I/II trial. Eur J Gastroenterol Hepatol. 20:1012–1019. 2008. View Article : Google Scholar : PubMed/NCBI
15	Schwartz JD, Sung M, Schwartz M, et al: Thalidomide in advanced hepatocellular carcinoma with optional low-dose interferon-alpha2a upon progression. Oncologist. 10:718–727. 2005. View Article : Google Scholar : PubMed/NCBI
16	Patt YZ, Hassan MM, Lozano RD, et al: Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer. 103:749–755. 2005. View Article : Google Scholar : PubMed/NCBI
17	Folkman J: Angiogenesis in cancer, vascular, rheumatoid and other disease. Nat Med. 1:27–31. 1995. View Article : Google Scholar : PubMed/NCBI
18	Higgins GM and Anderson RM: Experimental pathology of the liver - restoration of the liver of the white rat following partial surgical removal. Arch Pathol. 7:187–202. 1931.
19	Kwon AH, Uetsuji S, Yamamura M, Hioki K and Yamamoto M: Effect of administration of fibronectin or aprotinin on liver regeneration after experimental hepatectomy. Ann Surg. 211:295–300. 1990.PubMed/NCBI
20	Garcia N Jr and Sanyal AJ: Laboratory assessment of hepatic hemodynamics. Clin Liver Dis. 5:591–615. 2001. View Article : Google Scholar
21	Arvidsson D, Svensson H and Haglund U: Laser-Doppler flowmetry for estimating liver blood flow. Am J Physiol. 254(4 Pt 1): G471–G476. 1988.PubMed/NCBI
22	Sun Z, Klein AS, Radaeva S, et al: In vitro interleukin-6 treatment prevents mortality associated with fatty liver transplants in rats. Gastroenterology. 125:202–215. 2003. View Article : Google Scholar : PubMed/NCBI
23	Lopez-Talavera JC, Cadelina G, Olchowski J, Merril W and Groszmann RJ: Thalidomide inhibits tumor necrosis factors alpha, decreases nitric oxide synthesis, and ameliorates the hyperdynamic circulatory syndrome in portal-hypertensive rats. Hepatology. 23:1616–1621. 1996.
24	Bockhorn M, Goralski M, Prokofiev D, et al: VEGF is important for early liver regeneration after partial hepatectomy. J Surg Res. 138:291–299. 2007. View Article : Google Scholar : PubMed/NCBI